Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates - MSN
3 days ago • Google News
Immunome Inc (IMNM)
US$ 12.983.51%
Price Chart
Key Statistics
Market Cap
$ 744.83M
P/E Ratio
0.00
Revenue (TTM)
$ 10.94M
Volume
547.76K
52W High
$ 16.81
52W Low
$ 5.15
Dividend Yield
0.00%
Beta
2.01
Technicals
50-Day MA
7.7593
200-Day MA
11.0283
52 Week High
16.81
52 Week Low
5.1501
About IMNM
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies.
Employees
131
Headquarters
Bothell, WA
CEO
Dr. Clay B. Siegall Ph.D.
Latest News
Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha
2025-04-17 • Google News
Insider Purchase: Director at $IMNM Buys 7,800 Shares - Nasdaq
2025-03-26 • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg